The Role of IL-6 in Rheumatoid Arthritis: Mechanisms, Tocilizumab Efficacy, and Challenges in Treatment

Ruiheng Shao

doi:10.54097/78rk4d22

Authors

Ruiheng Shao

DOI:

https://doi.org/10.54097/78rk4d22

Keywords:

TCL, IL-6, rheumatoid arthritis, adverse effect.

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects small joints and soft tissues. Currently, several effective drugs, such as tocilizumab (TCZ), are used in clinical practice to control disease progression and alleviate symptoms. While these treatments offer significant benefits, adverse effects remain a challenge. This article explores the molecular mechanisms of IL-6 in RA pathology, emphasizing its role in disease development and symptom manifestation. Additionally, it reviews the efficacy of TCZ, highlighting both its therapeutic advantages and associated risks, such as increased susceptibility to infections and cardiovascular complications. The study suggests that future research should focus on minimizing these adverse effects while maintaining treatment efficacy. Moreover, multi-drug combination therapy is proposed as a potential strategy to improve patient outcomes. However, this article does not cover other cytokines involved in RA, such as IL-2 and IL-8, nor does it address all potential adverse effects. Further research is necessary to enhance treatment strategies and better manage RA-related risks.

Downloads

Download data is not yet available.

References

[1] Symmons D P M, Barrett E M, Bankhead C R, Scott D G L, Silman A J. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register [J]. Rheumatology, 1994, 33 (8): 735-739.

[2] Ma H, Liang X, Li S S, et al. The role of anti-citrullinated protein antibody in pathogenesis of RA [J]. Clinical and Experimental Medicine, 2024, 24 (1): 153.

[3] Bullock J, Rizvi S A A, Saleh A M, Ahmed S S, Do D P, Ansari R A, Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment [J]. Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre, 2018, 27 (6): 501–507.

[4] Hashizume M, Mihara M. The roles of interleukin‐6 in the pathogenesis of rheumatoid arthritis [J]. Arthritis, 2011, 2011 (1): 765624.

[5] Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis [J]. BioMed Research International, 2014, 2014 (1): 698313.

[6] Sheppard M, Laskou F, Stapleton P P, Hadavi S, Dasgupta B. Tocilizumab (Actemra) [J]. Human Vaccines & Immunotherapeutics, 2017, 13 (9): 1972-1988.

[7] Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K. A case of multicentric Castleman’s disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, Tocilizumab [J]. Journal of Korean Medical Science, 2010, 25 (9): 1364-1367.

[8] Kaneko A. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy [J]. Therapeutic Advances in Chronic Disease, 2013, 4 (1): 15-21.

[9] European Medicines Agency. Tocilizumab (RoActemra) 20 mg/mL concentrate solution for infusion/162 mg solution for injection in pre-filled syringe: summary of product characteristics [R]. 2016.

[10] Salmon J H, Perotin J M, Morel J, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data [J]. Rheumatology (Oxford), 2018, 57 (1): 134–139.

[11] Venkiteshwaran A. Tocilizumab [C] // MAbs. Taylor & Francis, 2009, 1 (5): 432-438.

[12] Symmons P M, Gabriel S E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE [J]. Rheumatology, 2011, 7: 399–408.

[13] Genovese M C, McKay J D, Nasonov E L, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study [J]. Arthritis Rheum, 2008, 58 (10): 2968-2980.

[14] Oldfield V, Dhillon S, Plosker G L. Tocilizumab: a review of its use in the management of rheumatoid arthritis [J]. Drugs, 2009, 69: 609-632.

[15] European Medicines Agency. Tocilizumab (RoActemra) 20 mg/mL concentrate solution for infusion/162 mg solution for injection in pre-filled syringe: summary of product characteristics [R]. 2016. Available from: http://www.ema.europa.eu. Accessed 2 Oct 2017.

[16] Rutherford A I, Subesinghe S, Hyrich K L, Galloway J B. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis [J]. Annals of the Rheumatic Diseases, 2018, 77 (6): 905-910.

[17] Scott L J. Tocilizumab: A Review in Rheumatoid Arthritis [J]. Drugs, 2017, 77 (17): 1865-1879. Erratum in: Drugs, 2018, 78 (2): 285.